UA66767C2
(uk)
|
1996-10-18 |
2004-06-15 |
Вертекс Фармасьютикалс Інкорпорейтед |
Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
JP3889708B2
(ja)
|
2000-11-20 |
2007-03-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎トリペプチド阻害剤
|
US6867185B2
(en)
*
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
PL215228B1
(pl)
|
2002-05-20 |
2013-11-29 |
Bristol Myers Squibb Co |
Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
|
DE60334205D1
(en)
|
2002-05-20 |
2010-10-28 |
Bristol Myers Squibb Co |
Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
|
JP4271148B2
(ja)
|
2002-05-20 |
2009-06-03 |
ブリストル−マイヤーズ スクイブ カンパニー |
置換シクロアルキルp1’c型肝炎ウイルスインヒビター
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US20050159345A1
(en)
*
|
2002-10-29 |
2005-07-21 |
Boehringer Ingelheim International Gmbh |
Composition for the treatment of infection by Flaviviridae viruses
|
US7176208B2
(en)
*
|
2003-04-18 |
2007-02-13 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
|
PT1654261E
(pt)
|
2003-05-21 |
2008-01-18 |
Boehringer Ingelheim Int |
Compostos inibidores da hepatite c
|
JP4928261B2
(ja)
|
2003-06-18 |
2012-05-09 |
トランザイム・ファーマ・インコーポレイテッド |
モチリン受容体の大環状拮抗薬
|
TWI359147B
(en)
|
2003-09-05 |
2012-03-01 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv n
|
JP4704342B2
(ja)
*
|
2003-09-22 |
2011-06-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎ウイルスに対し活性な大環状ペプチド
|
CN103145715B
(zh)
*
|
2003-10-14 |
2016-08-03 |
F·霍夫曼-罗须公司 |
作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
|
US7491794B2
(en)
*
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2539575C
(en)
|
2003-11-20 |
2015-01-20 |
Boehringer Ingelheim International Gmbh |
Method of removing transition metals, especially from metathesis reaction products
|
ATE424926T1
(de)
*
|
2003-12-08 |
2009-03-15 |
Boehringer Ingelheim Int |
Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
|
JP4682155B2
(ja)
*
|
2004-01-21 |
2011-05-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎ウイルスに対して活性な大環状ペプチド
|
WO2005073195A2
(en)
|
2004-01-30 |
2005-08-11 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
ES2431314T3
(es)
|
2004-02-20 |
2013-11-26 |
Boehringer Ingelheim International Gmbh |
Inhibidores de polimerasa vírica
|
WO2005095403A2
(en)
*
|
2004-03-30 |
2005-10-13 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
US7202332B2
(en)
|
2004-05-27 |
2007-04-10 |
New York University |
Methods for preparing internally constrained peptides and peptidomimetics
|
PL1778702T3
(pl)
*
|
2004-07-16 |
2011-12-30 |
Gilead Sciences Inc |
Związki przeciwwirusowe
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
JP4914355B2
(ja)
|
2004-07-20 |
2012-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎インヒビターペプチド類似体
|
US7189844B2
(en)
*
|
2004-09-17 |
2007-03-13 |
Boehringer Ingelheim International Gmbh |
Ring-closing metathesis process in supercritical fluid
|
US7375218B2
(en)
*
|
2004-09-17 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Process for preparing macrocyclic HCV protease inhibitors
|
EP2374464A3
(en)
|
2004-10-01 |
2011-10-26 |
Vertex Pharmaceuticals Incorporated |
HCV N3S-NS4A protease inhibition
|
US20070249637A1
(en)
*
|
2004-10-21 |
2007-10-25 |
Collins Michael R |
Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same
|
MY141025A
(en)
|
2004-10-29 |
2010-02-25 |
Vertex Pharma |
Dose forms
|
DE102005002336A1
(de)
*
|
2005-01-17 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2606195C
(en)
|
2005-05-02 |
2015-03-31 |
Merck And Co., Inc. |
Hcv ns3 protease inhibitors
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI387603B
(zh)
*
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Hcv ns3蛋白酶抑制劑
|
EP2305697A3
(en)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
US8278322B2
(en)
*
|
2005-08-01 |
2012-10-02 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
CA2618682C
(en)
|
2005-08-12 |
2011-06-21 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US8039475B2
(en)
|
2006-02-27 |
2011-10-18 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
WO2007109080A2
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
GB0609492D0
(en)
*
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
KR20090024834A
(ko)
*
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
US7935670B2
(en)
|
2006-07-11 |
2011-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7718612B2
(en)
*
|
2007-08-02 |
2010-05-18 |
Enanta Pharmaceuticals, Inc. |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
RU2009109355A
(ru)
|
2006-08-17 |
2010-09-27 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Ингибиторы вырусной полимеразы
|
CA2667165A1
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2007309544B2
(en)
*
|
2006-10-24 |
2012-05-31 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
CN101583372A
(zh)
*
|
2006-10-24 |
2009-11-18 |
默克公司 |
Hcv ns3蛋白酶抑制剂
|
JP5352464B2
(ja)
*
|
2006-10-27 |
2013-11-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Hcvns3プロテアーゼ阻害剤
|
KR101615500B1
(ko)
|
2006-10-27 |
2016-04-27 |
머크 샤프 앤드 돔 코포레이션 |
Hcv ns3 프로테아제 억제제
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2672250C
(en)
|
2006-12-20 |
2013-04-30 |
Ian Stansfield |
Antiviral indoles
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2111396B1
(en)
*
|
2007-02-08 |
2013-08-07 |
Janssen R&D Ireland |
Hcv inhibiting macrocyclic phenylcarbamates
|
JP2010519330A
(ja)
|
2007-02-27 |
2010-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
共結晶体およびそれを含む医薬組成物
|
CN101903392A
(zh)
|
2007-02-27 |
2010-12-01 |
弗特克斯药品有限公司 |
丝氨酸蛋白酶的抑制剂
|
AU2008251425A1
(en)
*
|
2007-05-10 |
2008-11-20 |
Array Biopharma, Inc. |
Novel peptide inhibitors of hepatitis C virus replication
|
WO2009005690A2
(en)
*
|
2007-06-29 |
2009-01-08 |
Gilead Sciences, Inc. |
Antiviral compounds
|
AU2008271117B2
(en)
|
2007-06-29 |
2013-10-24 |
Gilead Sciences, Inc. |
Antiviral compounds
|
AP2874A
(en)
|
2007-06-29 |
2014-03-31 |
Gilead Sciences Inc |
Antiviral compounds
|
CN101754970B
(zh)
|
2007-07-17 |
2013-07-10 |
P.安杰莱蒂分子生物学研究所 |
用于治疗丙型肝炎的大环吲哚衍生物
|
CA2699891C
(en)
|
2007-07-19 |
2013-10-22 |
Nigel Liverton |
Macrocyclic compounds as antiviral agents
|
EP2188274A4
(en)
|
2007-08-03 |
2011-05-25 |
Boehringer Ingelheim Int |
VIRAL POLYMERASE HEMMER
|
CN101835774B
(zh)
|
2007-08-30 |
2014-09-17 |
弗特克斯药品有限公司 |
共晶体和包含该共晶体的药物组合物
|
US8419332B2
(en)
*
|
2007-10-19 |
2013-04-16 |
Atlas Bolt & Screw Company Llc |
Non-dimpling fastener
|
EP2224942A4
(en)
|
2007-12-05 |
2012-01-25 |
Enanta Pharm Inc |
FLUORATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
|
CN101903351B
(zh)
|
2007-12-19 |
2014-09-10 |
贝林格尔.英格海姆国际有限公司 |
病毒聚合酶抑制剂
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
EP2250174B1
(en)
*
|
2008-02-04 |
2013-08-28 |
IDENIX Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
JP2011519364A
(ja)
|
2008-04-15 |
2011-07-07 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2011518882A
(ja)
|
2008-04-28 |
2011-06-30 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Hcvns3プロテアーゼ阻害剤
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2300491B1
(en)
|
2008-05-29 |
2016-01-06 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
DK2310095T3
(da)
|
2008-07-22 |
2012-12-10 |
Merck Sharp & Dohme |
Makrocykliske quinoxalinforbindelser som hcv-ns3-protease-inhibitorer
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2743912A1
(en)
|
2008-11-20 |
2010-05-27 |
Achillion Pharmaceuticals, Inc. |
Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2379579A1
(en)
*
|
2008-12-19 |
2011-10-26 |
Gilead Sciences, Inc. |
Hcv ns3 protease inhibitors
|
RU2011127080A
(ru)
|
2009-01-07 |
2013-02-20 |
Сайнексис, Инк. |
Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
|
EP2396028A2
(en)
|
2009-02-12 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
WO2010118078A1
(en)
|
2009-04-08 |
2010-10-14 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
WO2010132163A1
(en)
|
2009-05-13 |
2010-11-18 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic compounds as hepatitis c virus inhibitors
|
US8232246B2
(en)
*
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
EP2459582B1
(en)
|
2009-07-30 |
2015-05-27 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
RU2554087C2
(ru)
|
2009-12-18 |
2015-06-27 |
Айденикс Фармасьютикалз, Инк. |
5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
|
EP2528605A1
(en)
|
2010-01-29 |
2012-12-05 |
Vertex Pharmaceuticals Incorporated |
Therapies for treating hepatitis c virus infection
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
AR082215A1
(es)
|
2010-07-14 |
2012-11-21 |
Vertex Pharma |
Composicion farmaceutica agradable al paladar
|
EA029145B1
(ru)
|
2010-09-21 |
2018-02-28 |
Энанта Фармасьютикалз, Инк. |
Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина
|
KR20140003521A
(ko)
|
2010-12-30 |
2014-01-09 |
이난타 파마슈티칼스, 인코포레이티드 |
페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
|
EP2658859A4
(en)
|
2010-12-30 |
2014-07-30 |
Enanta Pharm Inc |
MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
WO2012109646A1
(en)
|
2011-02-11 |
2012-08-16 |
Vertex Pharmaceuticals Incorporated |
Treatment of hcv in hiv infection patients
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20130195797A1
(en)
|
2012-01-31 |
2013-08-01 |
Vertex Pharmaceuticals Incorporated |
High potency formulations of vx-950
|
CN102617705B
(zh)
*
|
2012-02-16 |
2014-12-31 |
上海纬诺医药科技有限公司 |
抑制丙肝病毒复制的大环类化合物
|
JP2015533124A
(ja)
|
2012-10-08 |
2015-11-19 |
アッヴィ・インコーポレイテッド |
Hcvプロテアーゼ阻害剤を作製するのに有用な化合物
|
AU2012392557B2
(en)
|
2012-10-19 |
2017-06-01 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914613B1
(en)
|
2012-11-02 |
2017-11-22 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070974A1
(en)
|
2012-11-05 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
CN105164148A
(zh)
|
2013-03-07 |
2015-12-16 |
百时美施贵宝公司 |
丙型肝炎病毒抑制剂
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
CN110256536B
(zh)
*
|
2019-05-13 |
2022-09-13 |
中国人民解放军第二军医大学 |
一种抗丙型肝炎病毒感染合成肽及其应用
|
CN117105928B
(zh)
*
|
2023-08-22 |
2024-03-26 |
上海蓝木化工有限公司 |
一种蛋白酶抑制剂及其制备方法
|